Advancing the understanding of placenta accreta spectrum disorder
A new study has identified targets to refine diagnostic tests, track disease progression, and discover more effective therapies.
List view / Grid view
A new study has identified targets to refine diagnostic tests, track disease progression, and discover more effective therapies.
For diseases mediated by NLRP3, AIM2, NLRC4, and Pyrin, understanding inflammasome biology could identify therapeutic targets.
3 January 2024 | By Eurofins DiscoverX
Watch this webinar to discover functional cell-based assays for characterizing novel therapeutics & biosimilars targeting cytokines in inflammation & oncology.
Download this exclusive content focusing on new RNA editing technology, the challenges and opportunities presented and the potential of RNA-based therapeutics.
A technique that can sort millions of CRISPR-edited cells based on their secretion patterns has been developed to treat autoimmune diseases.
Findings of rare CRISPR-linked gene modules and a novel CRISPR-Cas system have promising implications for genomic therapeutics.
Findings from using a 3D hydrogel to study how cancer cells physically tear the basement membrane offers promise for targeted treatment.
Researchers have developed an AI based model that is 80 percent accurate in predicting the therapy outcome of high-grade ovarian cancer.
New pathway involved in cellular protein degradation could develop LYTACs therapy and find new treatments for lysosome shortage disorders.
Scientists have developed ExoCaps, self-healing microcapsules that are more feasible than other cell-based technologies.
US researchers say new mechanism could lead to new drugs and therapies to treat normal cognitive decline in aging.
US researchers studied the extracellular vesicles of fibrosis and find potential avenue for new treatments and therapeutics.
20 July 2023 | By Eurofins DiscoverX
Watch this webinar to discover qualified bioassays assessing therapeutic antibody mechanisms, case studies about agonistic effects in antibodies initially deemed antagonistic, and explore Fc receptor impacts on antibody response in co-culture assays.
Dr Katie Abouzahr outlines how precision targeting utilising the neonatal fragment crystallisable receptor pathway may provide accessible new treatments for autoantibody diseases.
This articles aims to drive understanding in Antibody Drug Conjugate (ADC) drug development to improve patient outcomes. Petra Dieterich, Ian Glassford, and Jeff Mocny, Scientific Leaders at Abzena discuss real-world data that is challenging traditional scientific thinking on the ADC therapeutic window. The authors also explore the need for further…